Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics, Inc.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Cedric Francois

Pascal Deschatelets

Apellis Pharmaceuticals, Inc.

Hera BioLabs provides preclinical research services with a focus on gene editing. The company offers proprietary platforms and custom research models to support drug discovery and development.

Hera BioLabs

Kriya Therapeutics develops gene therapies for conditions affecting millions of people globally, with a focus on making these therapies accessible. The company targets areas of high unmet need, utilizing innovative gene therapy approaches.

Kriya Therapeutics

Sarepta Therapeutics is a biotechnology company focused on engineering precision genetic medicine to develop treatments for rare diseases. It engages in drug development and gene therapy manufacturing.

Metric
Company Name	Sarepta Therapeutics, Inc.	Apellis Pharmaceuticals, Inc.	Hera BioLabs	Kriya Therapeutics
Symbol	SRPT	APLS
MSH ID	COM:SAREPTA	COM:APELLIS	COM:HERABIOLABS	COM:KRIYATHERAPEUTICS
Market	STOCKS	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US	US
Stage	Post-IPO Equity		Venture Round	Series C
Employee Count	1.31K	702
Website	sarepta.com	apellis.com	herabiolabs.com	kriyatherapeutics.com
LinkedIn		apellis
Founders

Metric
Market Cap	14.11B	4.54B
Enterprise Value
Monthly Web Traffic	12.98K		1.41K	2.88K
Web Traffic Growth	-0.26		-0.46	-0.93
Valuation
Raised Capital	5.96M		1.07M	150M

Metric
Revenue	1.24B	396.59M
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.09B	336.38M
EBITDA	-267.82M	-515.42M
Operating Income	-267.82M	-517.12M
Net Income	-535.98M	-528.63M
EPS	-5.80	-4.45
Diluted EPS	-5.80	-4.45
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.88	0.86
Operating Profit Margin	0.03	-0.53
EBITDA Margin	-0.22	-1.30
Net Profit Margin	0.03	-0.54
Return on Equity	0.05	-1.39
Return on Assets	0.01	-0.37
Return on Capital Employed	0.01	-0.44

COM:SAREPTA

Sarepta Therapeutics

Last Close

110.50

22/11 21:00

Market Cap

14.11B

Beta: -

Volume Today

913.72K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-16.13	-13.43
P/B Ratio	14.58	35.03
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	11.03	17.50
EV Multiple	207.35	-9.71

Metric
Days Sales Outstanding	117.02	260.84
Days Payables Outstanding	234.37	159.91
Days Inventory Outstanding	958.33	913.04
Operating Cycle	1.05K	1.11K
Cash Conversion Cycle	841.56	886.42
Asset Turnover	0.44	0.68

Metric
Operating Cash Flow	-500.99M	-594.74M
Free Cash Flow	-588.34M	-595.51M
Cash Flow to Debt	-0.32	-0.88
Operating Cash Flow/Sales	-0.26	-0.66
Free Cash Flow Yield	-0.05	-0.08

Metric
Cash & Equivalents	428.43M	352.30M
Accounts Receivable	-185.70M	-198.72M
Inventory	322.86M	146.36M
Goodwill
Debt to Capitalization	0.59	0.64
Debt to Assets	0.54	0.13
Current Ratio	5.44	4.29
Quick Ratio	3.44	4.18

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.17	0.40
R&D to Revenue	0.81	1.47
SG&A to Revenue	0.43	1.69